No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease.

Thiel, U; Schober, S J; Ranft, A; Gassmann, H; Jabar, S; Gall, K; von Lüttichau, I; Wawer, A; Koscielniak, E; Diaz, M A; Ussowicz, M; Kazantsev, I; Afanasyev, B; Merker, M; Klingebiel, T; Prete, A; Gruhn, B; Bader, P; Jürgens, H; Dirksen, U; Handgretinger, R; Burdach, S; Lang, P

doi:10.1038/s41409-020-01200-x

journal article

Title:: No difference in survival after HLA mismatched versus HLA matched allogeneic stem cell transplantation in Ewing sarcoma patients with advanced disease.
Document type:: Journal Article; Research Support, Non-U.S. Gov't
Author(s):: Thiel, U; Schober, S J; Ranft, A; Gassmann, H; Jabar, S; Gall, K; von Lüttichau, I; Wawer, A; Koscielniak, E; Diaz, M A; Ussowicz, M; Kazantsev, I; Afanasyev, B; Merker, M; Klingebiel, T; Prete, A; Gruhn, B; Bader, P; Jürgens, H; Dirksen, U; Handgretinger, R; Burdach, S; Lang, P
Abstract:: Patients with advanced Ewing sarcoma (AES) carry a poor prognosis. Retrospectively, we analyzed 66 AES patients treated with allogeneic stem cell transplantation (allo-SCT) receiving HLA-mismatched (group A, n = 39) versus HLA-matched grafts (group B, n = 27). Median age at diagnosis was 13 years, and 15 years (range 3-49 years) at allo-SCT. The two groups did not differ statistically in distribution of gender, age, remission status/number of relapses at allo-SCT, or risk stratum. 9/39 (23%) group A versus 2/27 (7%) group B patients developed severe acute graft versus host disease (GvHD). Of patients alive at day 100, 7/34 (21%) group A versus 9/19 (47%) group B patients had developed chronic GvHD. In group A, 33/39 (85%) versus 20/27 (74%) group B patients died of disease and 1/39 (3%) versus 1/27 (4%) patients died of complications, respectively. Altogether 12/66 (18%) patients survived in CR. Median EFS 24 months after allo-SCT was 20% in both groups, median OS was 27% (group A) versus 17% (group B), respectively. There was no difference in EFS and OS in AES patients transplanted with HLA-mismatched versus HLA-matched graft in univariate and multivariate analyses. In this analysis, CR at allo-SCT is a condition for survival (p < 0.02).
Journal title abbreviation:: Bone Marrow Transplant
Year:: 2021
Journal volume:: 56
Journal issue:: 7
Pages contribution:: 1550-1557
Fulltext / DOI:: doi:10.1038/s41409-020-01200-x
Pubmed ID:: http://view.ncbi.nlm.nih.gov/pubmed/33514918
Print-ISSN:: 0268-3369
TUM Institution:: Klinik und Poliklinik für Kinder- und Jugendmedizin
BibTeX

Occurrences:

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Clinical Medicine Klinik und Poliklinik für Kinder- und Jugendmedizin (Prof. Hauer)2021